{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T01:26:16Z","timestamp":1763429176432},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2010,5,30]],"date-time":"2010-05-30T00:00:00Z","timestamp":1275177600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1007\/s00277-010-0993-2","type":"journal-article","created":{"date-parts":[[2010,5,29]],"date-time":"2010-05-29T11:18:03Z","timestamp":1275131883000},"page":"233-234","source":"Crossref","is-referenced-by-count":5,"title":["Complete molecular remission in a polycythaemia vera patient 12\u00a0years after discontinuation of interferon-alpha"],"prefix":"10.1007","volume":"90","author":[{"given":"Philip T.","family":"Murphy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne","family":"McPherson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen E.","family":"Langabeer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,5,30]]},"reference":[{"key":"993_CR1","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00277-008-0498-4","volume":"87","author":"TS Larsen","year":"2008","unstructured":"Larsen TS, Bjerrum OW, Pallisgaard N, Andersen MT, Moller MB, Hasselbalch HC (2008) Sustained major molecular response on interferon alpha-2b in two patients with polycythemia vera. Ann Hematol 87:847\u2013850","journal-title":"Ann Hematol"},{"key":"993_CR2","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/(SICI)1097-0142(19980915)83:6<1205::AID-CNCR21>3.0.CO;2-8","volume":"83","author":"HS Gilbert","year":"1998","unstructured":"Gilbert HS (1998) Long term treatment of myeloproliferative disease with interferon-alpha-2b. Feasibility and efficacy. Cancer 83:1205\u20131213","journal-title":"Cancer"},{"key":"993_CR3","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","volume":"112","author":"J-J Kiladjian","year":"2008","unstructured":"Kiladjian J-J, Cassinat B, Chevret S, Turlure P, Cambier N, Roussel M, Bellucci S, Grandchamp B, Chomienne C, Fenaux P (2008) Pegylated-interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 112:3065\u20133072","journal-title":"Blood"},{"key":"993_CR4","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1200\/JCO.2009.23.6075","volume":"27","author":"A Quintas-Cardama","year":"2009","unstructured":"Quintas-Cardama A, Kantarjian H, Manshouri T, Luthra R, Estrov Z, Pierce S, Richie MA, Borthakur G, Konopleva M, Cortes J, Verstovsek S (2009) Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 27:5418\u20135424","journal-title":"J Clin Oncol"},{"key":"993_CR5","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/MOH.0b013e3283366b91","volume":"17","author":"A Chen","year":"2010","unstructured":"Chen A, Prchal J (2010) JAK2 kinase inhibitors and myeloproliferative disorders. Curr Opin Hematol 17:110\u2013116","journal-title":"Curr Opin Hematol"},{"key":"993_CR6","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","volume":"365","author":"EJ Baxter","year":"1995","unstructured":"Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, The Cancer Genome Project, Green AR (1995) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365:1054\u20131061","journal-title":"Lancet"},{"key":"993_CR7","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/sj.leu.2404861","volume":"22","author":"TS Larsen","year":"2008","unstructured":"Larsen TS, Pallisgaard N, Moller MB, Hasselbalch HC (2008) Quantitative assessment of the JAK2 V617F allele burden: equivalent levels in peripheral blood and bone marrow. Leukemia 22:194\u2013195","journal-title":"Leukemia"},{"key":"993_CR8","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1182\/blood-2008-09-176818","volume":"113","author":"G Barosi","year":"2009","unstructured":"Barosi G, Birgegard G, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, Kiladjian JJ, Lengfelder E, McMullin MF, Passamonti F, Reilly JT, Vannucchi AM, Barbui T (2009) Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood 113:4829\u20134833","journal-title":"Blood"},{"key":"993_CR9","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/ajh.2830460110","volume":"46","author":"DH Cowan","year":"1994","unstructured":"Cowan DH, Messner HA, Jamal N, Aye MT, Smiley RK (1994) Spontaneous remission of polycythemia vera: clinical and cell culture characteristics. Am J Hematol 46:54\u201356","journal-title":"Am J Hematol"},{"key":"993_CR10","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00277-006-0214-1","volume":"86","author":"C Steimle","year":"2007","unstructured":"Steimle C, Lehmann U, Temerinac S, Goerttler Ph S, Kreipe H, Meinhardt G, Heimpel H, Pahl HL (2007) Biomarker analysis in polycythemia vera under interferon-alpha treatment: clonality, EEC, PRV-1, and JAK2 V617F. Ann Hematol 86:239\u2013244","journal-title":"Ann Hematol"},{"key":"993_CR11","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1365-2141.2005.05606.x","volume":"130","author":"GR Angstreich","year":"2005","unstructured":"Angstreich GR, Matsui W, Huff CA, Vala MS, Barber J, Hawkins AL, Griffin CA, Smith BD, Jones RJ (2005) Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors. Br J Haematol 130:373\u2013381","journal-title":"Br J Haematol"},{"key":"993_CR12","unstructured":"Sacchi S, Cortes J, Kantarjian H, Talpaz M (1997-1998) Effects of interferon-alpha therapy on lymphocyte subpopulations in patients with chronic myeloid leukemia. Hematopathol Mol Hematol 11: 41-47"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-010-0993-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-010-0993-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-010-0993-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T05:50:13Z","timestamp":1559022613000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-010-0993-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,30]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["993"],"URL":"https:\/\/doi.org\/10.1007\/s00277-010-0993-2","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5,30]]}}}